T5857 |
Trametinib (DMSO solvate)
|
1187431-43-1
|
100%
|
|
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a Highly Potent and Selective MEK Inhibitor that specifically inhibits MEK1/2(IC50 :2 nM)
|
T2708 |
SL327
|
305350-87-2
|
100%
|
|
SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier.
|
T1144 |
Lidocaine hydrochloride
|
73-78-9
|
100%
|
|
Lidocaine hydrochloride (Lignocaine hydrochloride) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and...
|
T0468 |
Lidocaine
|
137-58-6
|
98%
|
|
Lidocaine (Alphacaine) is an amide local anesthetic with anti-inflammatory properties in vitro and in vivo. It has this functions perhaps due to an attenuation o...
|
T1744 |
BIX02188
|
334949-59-6
|
98%
|
|
BIX02188 is a selective and potent MEK5 inhibitor that inhibits MEK5-induced apoptosis in cells expressing the oncogenic mutant FLT3-ITD.
|
T6636 |
Refametinib
|
923032-37-5
|
98%
|
|
Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).
|
T6843 |
GDC-0623
|
1168091-68-6
|
98%
|
|
GDC-0623 (RG 7421) is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
|
T21547 |
PAF (C16)
|
74389-68-7
|
98%
|
|
PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholi...
|
T6692 |
TAK-733
|
1035555-63-5
|
98%
|
|
TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
|
T21295 |
BIX02189
|
1265916-41-3
|
98%
|
|
BIX02189 is a potent and selective inhibitor of MEK5 and ERK5(IC50 : 1.5 nM and 59 nM).
|
T6057 |
URMC-099
|
1229582-33-5
|
98%
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|